# OnCo record checkmate-548 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/checkmate-548/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "checkmate-548", "NCT02667587" ;
  schema:name "CheckMate 548"@en ;
  schema:description "CheckMate 548 added nivolumab to standard radiotherapy and temozolomide in newly diagnosed glioblastoma and found no benefit. With CheckMate 143 and 498 it makes three large negative trials: the immunotherapy that transformed melanoma and lung cancer did nothing in glioblastoma."@en ;
  schema:url <https://onco.cc/trials/checkmate-548/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02667587>, <https://doi.org/10.1093/neuonc/noac116> ;
  onco:status "negative" ;
  onco:phase "3" ;
  schema:startDate "2016-05-09" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/temozolomide/> ;
  onco:terms <https://onco.cc/terms/mgmt/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/blood-brain-barrier/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-lim-neuro-oncol/> .